Breakthrough Non-narcotic Peptide Analgesic
The discovery phase has been over 25 years.
Now Preclinical study is 100% completed.
About
ANODYNAL® is painkiller for various methods of parenteral administration in a wide range of nociceptive and neuropathic pains.
No risk of drug addiction
which opioids has
No side-effect and toxicity
which NSAIDs has
No specific disadvantages
of full-size calcitonin molecule
How It Works
Possible drug form is nasal drops.
1
Chemical Structure
Synthetic analogue of the salmon calcitonin molecule fragment, which retains the analgesic activity of the full-size molecule.
It was selected and patented 288 variants of peptide sequences differing most stability and analgesic effectiveness (Patent "Synthetic peptides wtih a non-narcotic type of analgesic effect", WO2013141750A1).
It was selected and patented 288 variants of peptide sequences differing most stability and analgesic effectiveness (Patent "Synthetic peptides wtih a non-narcotic type of analgesic effect", WO2013141750A1).
2
Mechanism of action
The analgesic effect of ANODYNAL® is associated with a specific binding of a clathrin heavy chain.
Inhibition of clathrin-mediated endocytosis (CME) by clathrin blockage leads to irregular recycling of pain receptors in the postsynaptic vesicular cycle, which results in the analgesic effect.
This innovative mechanism of ANODYNAL® action has been patented (Patent "Specific peptide inhibitors of clathrin" WO2018186770A1).
Inhibition of clathrin-mediated endocytosis (CME) by clathrin blockage leads to irregular recycling of pain receptors in the postsynaptic vesicular cycle, which results in the analgesic effect.
This innovative mechanism of ANODYNAL® action has been patented (Patent "Specific peptide inhibitors of clathrin" WO2018186770A1).
3
Сomparison with other analgesics
The analgesic effect of ANODYNAL® is comparable to morphine and higher than that of ketorolac tromethamine, which is significantly superior to other NSAIDs, at doses 1000 times less and cost 3 times less.
Source: Arkady M Kotin, Maksim O Emelyanov and Oleg A Kotin «Low-molecular synthetic peptides with non-narcotic type of analgesia: comparative study and mechanism of analgesic activity», Molecular Pain, 2019, Volume 15: 1–13.
Source: Arkady M Kotin, Maksim O Emelyanov and Oleg A Kotin «Low-molecular synthetic peptides with non-narcotic type of analgesia: comparative study and mechanism of analgesic activity», Molecular Pain, 2019, Volume 15: 1–13.
Opioid epidemic: key facts
- Beginning in the 1980s, prescription opioids like oxycodone and hydrocodone were heavily marketed as a treatment for pain, and at the time, the risk of addiction to these substances was downplayed.
- Opioid prescriptions nearly tripled between 1991 and 2011.
- In 2015, nearly 100 million Americans were prescribed painkillers by their doctor.
- 70 K opioid drug overdose deaths were registered in 2017 in the US.
- Now drug overdoses are the leading cause of death for Americans under the age of 50, who are now more likely to die from a drug overdose than from car accidents or firearms.
anodynal.com